Xeris Biopharma Holdings (FRA:2B30) LT-Debt-to-Total-Asset : 0.78 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Xeris Biopharma Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Xeris Biopharma Holdings's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.78.

Xeris Biopharma Holdings's long-term debt to total assets ratio increased from Mar. 2023 (0.61) to Mar. 2024 (0.78). It may suggest that Xeris Biopharma Holdings is progressively becoming more dependent on debt to grow their business.

Xeris Biopharma Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Xeris Biopharma Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings LT-Debt-to-Total-Asset Chart

Xeris Biopharma Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.54

0.55

0.29

0.57

0.70

Xeris Biopharma Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.61	0.68	0.69	0.70	0.78

Xeris Biopharma Holdings LT-Debt-to-Total-Asset Calculation

Xeris Biopharma Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	206.963	/	295.826
	=	0.70

Xeris Biopharma Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	242.945	/	309.687
	=	0.78

Xeris Biopharma Holdings (FRA:2B30) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Xeris Biopharma Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Xeris Biopharma Holdings (FRA:2B30) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (FRA:2B30) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

XERS:USA 0A8E:UK

Address

180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601

Website

https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.

Xeris Biopharma Holdings (FRA:2B30) Headlines

No Headlines